Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma.

Lange S, Lampe J, Bossow S, Zimmermann M, Neubert W, Bitzer M, Lauer UM.

Hum Gene Ther. 2013 May;24(5):554-64. doi: 10.1089/hum.2012.136.

2.

Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.

Hartkopf AD, Bossow S, Lampe J, Zimmermann M, Taran FA, Wallwiener D, Fehm T, Bitzer M, Lauer UM.

Gynecol Oncol. 2013 Aug;130(2):362-8. doi: 10.1016/j.ygyno.2013.05.004. Epub 2013 May 12.

PMID:
23676551
3.

Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene.

Yurttas C, Berchtold S, Malek NP, Bitzer M, Lauer UM.

Hum Gene Ther Clin Dev. 2014 Jun;25(2):85-96. doi: 10.1089/humc.2013.127.

PMID:
24933569
4.

Primary resistance phenomena to oncolytic measles vaccine viruses.

Noll M, Berchtold S, Lampe J, Malek NP, Bitzer M, Lauer UM.

Int J Oncol. 2013 Jul;43(1):103-12. doi: 10.3892/ijo.2013.1914. Epub 2013 Apr 23.

PMID:
23612727
5.

An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis.

Lampe J, Bossow S, Weiland T, Smirnow I, Lehmann R, Neubert W, Bitzer M, Lauer UM.

Gene Ther. 2013 Nov;20(11):1033-41. doi: 10.1038/gt.2013.28. Epub 2013 May 30.

PMID:
23719065
6.

Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis.

Berchtold S, Lampe J, Weiland T, Smirnow I, Schleicher S, Handgretinger R, Kopp HG, Reiser J, Stubenrauch F, Mayer N, Malek NP, Bitzer M, Lauer UM.

J Virol. 2013 Mar;87(6):3484-501. doi: 10.1128/JVI.02106-12. Epub 2013 Jan 9.

7.

"PULSED" versus "CONTINUOUS" application of the prodrug 5-FC for enhancing oncolytic effectiveness of a measles vaccine virus armed with a suicide gene.

Yurttas C, Berchtold S, Malek N, Bitzer M, Lauer UM.

Hum Gene Ther Clin Dev. 2014 Apr 21. [Epub ahead of print]

PMID:
24749489
8.

Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.

Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G.

J Invest Dermatol. 2013 Apr;133(4):1034-42. doi: 10.1038/jid.2012.459. Epub 2012 Dec 6.

9.

Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.

Pederson LC, Buchsbaum DJ, Vickers SM, Kancharla SR, Mayo MS, Curiel DT, Stackhouse MA.

Cancer Res. 1997 Oct 1;57(19):4325-32.

10.

Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models.

Kojima Y, Honda K, Hamada H, Kobayashi N.

J Surg Res. 2009 Nov;157(1):e63-70. doi: 10.1016/j.jss.2008.12.016. Epub 2009 Jan 10.

PMID:
19345377
11.

Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.

Zaoui K, Bossow S, Grossardt C, Leber MF, Springfeld C, Plinkert PK, Kalle Cv, Ungerechts G.

Cancer Gene Ther. 2012 Mar;19(3):181-91. doi: 10.1038/cgt.2011.75. Epub 2011 Nov 11.

PMID:
22076043
12.

Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.

Yamada S, Kuroda T, Fuchs BC, He X, Supko JG, Schmitt A, McGinn CM, Lanuti M, Tanabe KK.

Cancer Gene Ther. 2012 Mar;19(3):160-70. doi: 10.1038/cgt.2011.70. Epub 2011 Nov 11.

13.

Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma.

Pugalenthi A, Mojica K, Ady JW, Johnsen C, Love D, Chen NG, Aguilar RJ, Szalay AA, Fong Y.

Cancer Gene Ther. 2015 Dec;22(12):591-6. doi: 10.1038/cgt.2015.60. Epub 2015 Nov 20.

PMID:
26584530
14.

Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.

Hutzen B, Bid HK, Houghton PJ, Pierson CR, Powell K, Bratasz A, Raffel C, Studebaker AW.

BMC Cancer. 2014 Mar 19;14:206. doi: 10.1186/1471-2407-14-206.

15.

Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.

Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gonen M, Ebright MI, Culliford A, Gusani NJ, Fong Y.

Cancer Gene Ther. 2006 Mar;13(3):326-34.

PMID:
16138120
16.

Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.

Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.

Hum Gene Ther. 2013 Jul;24(7):644-54. doi: 10.1089/hum.2012.205.

17.

Oncolytic measles virus strains as novel anticancer agents.

Msaouel P, Opyrchal M, Domingo Musibay E, Galanis E.

Expert Opin Biol Ther. 2013 Apr;13(4):483-502. doi: 10.1517/14712598.2013.749851. Epub 2013 Jan 6. Review.

18.

Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.

Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC 3rd, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL.

Cancer Gene Ther. 2012 Sep;19(9):659-65. doi: 10.1038/cgt.2012.47. Epub 2012 Jul 13.

PMID:
22790962
19.

Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.

Tan DQ, Zhang L, Ohba K, Ye M, Ichiyama K, Yamamoto N.

Eur J Immunol. 2016 Apr;46(4):919-28. doi: 10.1002/eji.201545915. Epub 2016 Feb 3.

20.

Engineered measles virus as a novel oncolytic therapy against prostate cancer.

Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E.

Prostate. 2009 Jan 1;69(1):82-91. doi: 10.1002/pros.20857.

Supplemental Content

Support Center